Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.40 |
| ▸ | CASP3 | P42574 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29233231 | 0.90 | KMT2A (0.46) | KMT2ACASP3EPHX2 | |
| SCHEMBL29233233 | 0.90 | KMT2A (0.46) | KMT2ACASP3EPHX2 | |
| SCHEMBL31217947 | 0.86 | KMT2A (0.48) | KMT2APTPN1OPRD1ALDH1A1EPHX2 | |
| SCHEMBL29540687 | 0.86 | KMT2A (0.48) | KMT2APTPN1OPRD1ALDH1A1EPHX2 | |
| SCHEMBL16867593 | 0.86 | KMT2A (0.48) | KMT2APTPN1OPRD1ALDH1A1EPHX2 | |
| SCHEMBL31235852 | 0.85 | KMT2A (0.46) | KMT2APTPN1OPRD1ALDH1A1EPHX2 | |
| SCHEMBL30620557 | 0.84 | KMT2A (0.43) | KMT2AOPRD1CASP3ALDH1A1EPHX2 | |
| SCHEMBL30712760 | 0.84 | KMT2A (0.43) | KMT2AOPRD1CASP3ALDH1A1EPHX2 | |
| SCHEMBL30705439 | 0.84 | KMT2A (0.53) | KMT2AOPRD1CASP3ALDH1A1EPHX2 | |
| SCHEMBL31089986 | 0.84 | KMT2A (0.47) | KMT2APTPN1OPRD1CASP3ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4642484-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | Hangzhou Seehe Biotechnology Co., Ltd (CN) | 2025-11-05 | — | — | EP | disclosed |
| WO-2024239281-A1 | TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE | HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) | 2024-11-28 | — | — | WO | disclosed |
| EP-4426741-A1 | BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE | Hangzhou DAC Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| EP-4426729-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | Hangzhou Dac Biotech Co., Ltd. (CN) | 2024-09-11 | — | — | EP | disclosed |
| CN-118434765-A | BCMA monoclonal antibodies and antibody-drug conjugates | 杭州多禧生物科技有限公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-118215676-A | Specific conjugation of antibody drug conjugates | 杭州多禧生物科技有限公司 | 2024-06-18 | — | — | CN | disclosed |
| WO-2023078021-A1 | BCMA MONOCLONAL ANTIBODY AND THE ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |
| WO-2023078273-A1 | SPECIFIC CONJUGATION FOR AN ANTIBODY-DRUG CONJUGATE | HANGZHOU DAC BIOTECH CO., LTD. (CN) | 2023-05-11 | — | — | WO | disclosed |